Locoregional Management of Breast Cancer with SABCS Updates

This activity covers the following presentations:

  • Updates to Radiation Therapy for DCIS and Invasive Breast Cancer with SABCS Updates
  • Surgical Management of Invasive Breast Cancer with SABCS Updates

Target Audience

This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, PAs, pharmacists, social workers, and other health care professionals who manage patients with breast cancer.

Learning Objectives

Following this program, participants should be able to:

Updates to Radiation Therapy for DCIS and Invasive Breast Cancer with SABCS Updates

  • Develop an evidence-based approach for use of adjuvant radiation therapy for invasive non-metastatic breast cancer.
  • Discuss current and emerging radiation treatment modalities for invasive non-metastatic breast cancer.

Surgical Management of Invasive Breast Cancer with SABCS Updates

  • Individualize surgical management recommendations for invasive non-metastatic breast cancer.
  • Discuss current and emerging data in the treatment of invasive non-metastatic breast cancer and integrate key findings into clinical practice.
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca; Gilead Sciences, Inc.; Menarini-Stemline; Novartis; Puma Biotechnology; and Seagen. This activity is supported by independent educational grants from Daiichi Sankyo and Merck & Co., Inc., Rahway, NJ, USA. This activity is supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
Course opens: 
03/15/2024
Course expires: 
03/15/2025
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2024 Breast Cancer Congress with Updates from the 2023 San Antonio Breast Cancer Symposium

Meena S. Moran, MD
Yale Cancer Center/Smilow Cancer Hospital

Laura H. Rosenberger, MD, MS
Duke Cancer Institute

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Meena S. Moran, MD
Laura H. Rosenberger, MD, MS

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Daiichi-Sankyo Co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-24-025-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until March 15, 2025. PAs should only claim credit commensurate with the extent of their participation.

Social Workers
As a Jointly Accredited Organization, NCCN is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NCCN maintains responsibility for this course. Social workers completing this course receive 1.25 continuing education credits.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing